140 related articles for article (PubMed ID: 29181493)
1. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
Alam J; Blackburn K; Patrick D
J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
[TBL] [Abstract][Full Text] [Related]
3. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
[TBL] [Abstract][Full Text] [Related]
4. Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.
Alam JJ; Krakovsky M; Germann U; Levy A
PLoS One; 2020; 15(12):e0233073. PubMed ID: 33275615
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
Jiang Y; Alam JJ; Gomperts SN; Maruff P; Lemstra AW; Germann UA; Stavrides PH; Darji S; Malampati S; Peddy J; Bleiwas C; Pawlik M; Pensalfini A; Yang DS; Subbanna S; Basavarajappa BS; Smiley JF; Gardner A; Blackburn K; Chu HM; Prins ND; Teunissen CE; Harrison JE; Scheltens P; Nixon RA
Nat Commun; 2022 Sep; 13(1):5308. PubMed ID: 36130946
[TBL] [Abstract][Full Text] [Related]
6. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
Roy SM; Grum-Tokars VL; Schavocky JP; Saeed F; Staniszewski A; Teich AF; Arancio O; Bachstetter AD; Webster SJ; Van Eldik LJ; Minasov G; Anderson WF; Pelletier JC; Watterson DM
ACS Chem Neurosci; 2015 Apr; 6(4):666-80. PubMed ID: 25676389
[TBL] [Abstract][Full Text] [Related]
7. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ
J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271
[TBL] [Abstract][Full Text] [Related]
8. Neflamapimod induces vasodilation in resistance mesenteric arteries by inhibiting p38 MAPKα and downstream Hsp27 phosphorylation.
Pandey AK; Zerin F; Menon SN; Tithi TI; Nguyen KP; Vo T; Daniel ML; Hafez S; Alam MA; Hasan R
Sci Rep; 2022 Mar; 12(1):4905. PubMed ID: 35318382
[TBL] [Abstract][Full Text] [Related]
9. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
[TBL] [Abstract][Full Text] [Related]
10. VX-745. Vertex Pharmaceuticals.
Haddad JJ
Curr Opin Investig Drugs; 2001 Aug; 2(8):1070-6. PubMed ID: 11892915
[TBL] [Abstract][Full Text] [Related]
11. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
Alam JJ; Maruff P; Doctrow SR; Chu HM; Conway J; Gomperts SN; Teunissen C
Neurology; 2023 Oct; 101(17):e1708-e1717. PubMed ID: 37657939
[TBL] [Abstract][Full Text] [Related]
12. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
15. Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease.
Lanté F; Chafai M; Raymond EF; Pereira AR; Mouska X; Kootar S; Barik J; Bethus I; Marie H
Neuropsychopharmacology; 2015 Jun; 40(7):1772-81. PubMed ID: 25622751
[TBL] [Abstract][Full Text] [Related]
16. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.
Yu Q; Du F; Douglas JT; Yu H; Yan SS; Yan SF
J Alzheimers Dis; 2017; 59(1):223-239. PubMed ID: 28598851
[TBL] [Abstract][Full Text] [Related]
18. Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats.
Alam JJ
J Alzheimers Dis; 2015; 48(1):219-27. PubMed ID: 26401942
[TBL] [Abstract][Full Text] [Related]
19. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
[TBL] [Abstract][Full Text] [Related]
20. An exploratory clinical study of p38
Scheltens P; Prins N; Lammertsma A; Yaqub M; Gouw A; Wink AM; Chu HM; van Berckel BNM; Alam J
Ann Clin Transl Neurol; 2018 Apr; 5(4):464-473. PubMed ID: 29687023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
